Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on February 11, 2019, reporting an event that occurred on February 5, 2019. The filing addresses a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Director Appointment: Binxian Wei has been appointed to replace Xi Chen as the director appointee for the Company's Series A 4.5% Convertible Preferred Stock.
- Shareholder Action: The appointment was initiated by Tianjin Pharmaceuticals Group International Holdings Co., LTD, the sole shareholder of the Series A Stock.
- Term: Mr. Wei will serve as a Class III director until the 2020 annual shareholder meeting or until resignation/removal.
- Compensation: Mr. Wei will participate in the existing non-executive board compensation plan.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It confirms there are no family relationships between Mr. Wei and existing executive officers or directors.
Investor Verification Checklist
- Verify the identity and background of the new director, Binxian Wei.
- Confirm the terms of the Series A 4.5% Convertible Preferred Stock held by Tianjin Pharmaceuticals Group.
- Review the non-executive board compensation plan referenced from the June 27, 2017 filing.
- Check for any subsequent filings regarding the 2020 annual shareholder meeting.